Another potential genomic test for prostate cancer aggression

In a presentation given last Saturday at the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) in Vienna, a Canadian research team introduced yet another potential test that may be helpful in differentiating between patients at relatively high or low risk for metastasis, based on biopsy tissue. … READ MORE …

Is new oncogenic signature test really as good as the PR?

According to an article published on line in Cancer Research, a research team at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia is claiming that they have identified an “oncogene signature” that is highly predictive for aggressive forms of prostate cancer. … READ MORE …

Gene signatures, prognosis, and treatment of men with CRPC

We are clearly getting closer to being able to make accurate projections about which forms of castration-resistant prostate cancer (CRPC) are really aggressive and need immediate, aggressive therapeutic intervention and which are likely to progress more slowly (over a period of years). However, this is only the beginning of the story. … READ MORE …

The news report: Friday, April 17, 2009

In today’s news reports we address:

  • Prediction of freedom from biochemical failure after brachytherapy
  • Prediction of probability of unilateral prostate cancer in men eligible for focal therapy
  • Health-related quality of life 5 years after radiotherapy + androgen deprivation
  • Androgen receptor activity “signatures” in men with CRPC … READ MORE …